American Association for Cancer Research
00085472can182032-sup-204604_3_supp_5108172_pg5qy4.pdf (160.61 kB)

Figure S1 from A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT

Download (160.61 kB)
journal contribution
posted on 2023-03-31, 02:21 authored by Andrew V. Kossenkov, Rehman Qureshi, Noor B. Dawany, Jayamanna Wickramasinghe, Qin Liu, R. Sonali Majumdar, Celia Chang, Sandy Widura, Trisha Kumar, Wen-Hwai Horng, Eric Konnisto, Gerard Criner, Jun-Chieh J. Tsay, Harvey Pass, Sai Yendamuri, Anil Vachani, Thomas Bauer, Brian Nam, William N. Rom, Michael K. Showe, Louise C. Showe

NanoString platform quality controls


PA Department of Health





Low-dose CT (LDCT) is widely accepted as the preferred method for detecting pulmonary nodules. However, the determination of whether a nodule is benign or malignant involves either repeated scans or invasive procedures that sample the lung tissue. Noninvasive methods to assess these nodules are needed to reduce unnecessary invasive tests. In this study, we have developed a pulmonary nodule classifier (PNC) using RNA from whole blood collected in RNA-stabilizing PAXgene tubes that addresses this need. Samples were prospectively collected from high-risk and incidental subjects with a positive lung CT scan. A total of 821 samples from 5 clinical sites were analyzed. Malignant samples were predominantly stage 1 by pathologic diagnosis and 97% of the benign samples were confirmed by 4 years of follow-up. A panel of diagnostic biomarkers was selected from a subset of the samples assayed on Illumina microarrays that achieved a ROC-AUC of 0.847 on independent validation. The microarray data were then used to design a biomarker panel of 559 gene probes to be validated on the clinically tested NanoString nCounter platform. RNA from 583 patients was used to assess and refine the NanoString PNC (nPNC), which was then validated on 158 independent samples (ROC-AUC = 0.825). The nPNC outperformed three clinical algorithms in discriminating malignant from benign pulmonary nodules ranging from 6–20 mm using just 41 diagnostic biomarkers. Overall, this platform provides an accurate, noninvasive method for the diagnosis of pulmonary nodules in patients with non–small cell lung cancer. These findings describe a minimally invasive and clinically practical pulmonary nodule classifier that has good diagnostic ability at distinguishing benign from malignant pulmonary nodules.